Express Scripts Holding Co. said it expects adjusted EPS of $7.67 to $7.87 from its consolidated business in 2018.
The S&P Capital IQ consensus normalized EPS estimate for 2018 is $7.75.
The pharmacy benefit manager forecast 2018 revenue of between $99 billion to $102 billion.
Adjusted EBITDA for 2018 is expected to be between $7.6 billion and $7.8 billion.
Express Scripts said its restructuring effort, dubbed an enterprise value initiative, is estimated to cost about $600 million to $650 million and will deliver cumulative savings of nearly $1.2 billion by 2021.
The company's 2018 full-year guidance includes an estimated contribution of $65 million to $75 million in expense savings affecting the core and consolidated businesses.
For 2017, the U.S.-based company raised its forecast for adjusted EPS to $7.00 to $7.08 from the $6.97 to $7.05 range announced earlier this year.
The S&P Capital IQ consensus normalized EPS estimate for 2017 is $7.01.
The company, however, narrowed its 2017 adjusted EBITDA guidance to a range of $7.37 billion to $7.45 billion from $7.35 billion to $7.47 billion.